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Abstract
Activation of the transforming growth factor (TGF) α/epidermal growth factor receptor (EGFR)–mediated signaling
pathway is a common mechanism for dysregulated growth of head and neck squamous cell carcinoma (HNSCC).
c-Cbl–interacting protein of 85 kDa (CIN85) is an adaptor protein that facilitates EGFR internalization. Little is known,
however, about a role of CIN85 in EGFR signaling as well as its relevance to tumor development and progression of
HNSCC. Here, we demonstrate that CIN85 is highly expressed in HNSCC tumor samples compared with adjacent
normal tissues, and this overexpression is significantly correlated with advanced clinical stage. The experiments
using CIN85-overexpressing and knockdown HNSCC cell lines showed that CIN85 promotes HNSCC growth and
facilitates EGFR internalization without apparently affecting phosphorylation of EGFR. Moreover, CIN85 promoted
TGF-α–induced activation of Ras and phosphorylation of downstreammolecules such as c-Raf, MEK, and extracellular
signal–regulated kinase, leading to expression of c-Myc that is critical for sustained proliferation of HNSCC. Taken
together, these findings suggest that CIN85 not only controls EGFR internalization but also promotes the EGFR-
mediated tumor development and progression, and thus, CIN85may serve as a potential therapeutic target in a subset
of HNSCC.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most
common form of cancer worldwide. Despite recent advancements in
therapeutic strategies including surgery, radiotherapy, and chemotherapy,
the prognosis of HNSCC patients in advanced stages remains largely
unsatisfactory [1]. In this regard, growing interests are currently being
focused on the development of molecular-targeted therapies for this
group of patients. Notably, overexpression of epidermal growth factor
receptor (EGFR) and its ligand transforming growth factor (TGF) α is
commonly observed in a majority (80%-100%) of HNSCC and is
associated with poor prognosis of patients [1,2]. However, molecular-
targeted therapies with inhibitors of EGFR alone or in combination with
conventional treatments have thus far shown only limited efficacy [1].
A possible explanation for this failed response of HNSCC to EGFR
inhibitors is that downstream signaling pathways could be activated as
well by surrogate growth factors or cytokines. Nevertheless, the most
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tantalizing issue that precludes us from developing alternative strategies
to overcome such insensitivity would be a relative paucity of our un-
derstanding of downstream signaling pathways of EGFR that are criti-
cal for the maintenance of malignant phenotypes of HNSCC. These
signaling cascades include Ras/Raf/extracellular signal–regulated ki-
nase (ERK), signal transducers and activators of transcription (STATs)
and PI3K/Akt [1,3–6]. We and other investigators demonstrated that
STAT3 activation plays critical roles in downstream signaling of TGF-
α/EGFR in diverse steps, and this activation is profoundly associated
with the development and progression of HNSCC [5–7]. STAT3 ac-
tivation is, however, observed in less than 50% of HNSCC, suggest-
ing that TGF-α/EGFR can also transmit its growth signals by using
STAT3-independent downstream pathways. The Ras/Raf/ERK path-
way is activated and required for malignant transformation in a variety
of human malignancies by regulating cell cycle progression and cel-
lular survival (i.e., inhibition of apoptosis). Indeed, enhanced ERK
activation in HNSCC is associated with advanced regional lymph
node metastasis [4]. However, mechanisms of enhanced ERK ac-
tivation in HNSCC are not clearly elucidated, although high expres-
sion levels of K-ras in HNSCC only partly account for enhanced ERK
activation [8]. Collectively, the entire molecular circuitry downstream
of EGFR has not yet been elucidated in HNSCC. In this context,
more precise mechanistic study on the EGFR signaling pathways
would be an urgent task for developing novel therapeutic strategies
for HNSCC.
CIN85, c-Cbl–interacting protein of 85 kDa, is a widely expressed
multifunctional adaptor protein consisting of three N-terminal SH3
domains, a centrally located proline-rich motif and a C-terminal
coiled-coil domain [9,10]. CIN85 can interact with numerous proteins,
and the list of these partner proteins is rapidly growing [11]. One of
characteristic functions of CIN85 is the regulation of ligand-induced
internalization of receptor tyrosine kinases (RTKs) including EGFRs
[12,13]. Little is known, however, about a role of CIN85 in EGFR sig-
naling pathways as well as its relevance to the tumor development and
progression of HNSCC.
In the present study, we demonstrate that CIN85 is highly expressed
in HNSCC tumor samples compared with adjacent normal tissues, and
this overexpression is significantly correlated with advanced clinical
stage. In vitro experiments showed that CIN85 not only facilitates
EGFR internalization but also promotes HNSCC growth. In addi-
tion, CIN85 potentiated TGF-α–induced activation of Ras and phos-
phorylation of downstream molecules such as c-Raf, MEK, and ERK,
culminating in expression of c-Myc that is critical for HNSCC tumori-
genesis. These findings suggest that CIN85 not only controls EGFR
internalization but also promotes the EGFR-mediated cancer cell
growth pathway that is crucial for the tumor development and progres-
sion, and thus, CIN85 may serve as a potential therapeutic target in a
subset of HNSCC.
Materials and Methods
Clinical Samples
Twenty-nine cancer tissues along with adjacent normal tissues were
obtained from untreated patients with oral squamous cell carcinoma
who underwent surgical resection at Kyushu University Hospital be-
tween March 1997 and March 2008. The tissues were snap-frozen in
liquid nitrogen immediately after resection and stored at −80°C until
further use.
Cell Lines, Cell Culture, and Reagents
The human oral SCC cell line KB was generously provided by
Dr Michihiko Kuwano (Kurume University, Fukuoka, Japan), the
hypopharyngeal SCC cell line YCU-H891 was provided by DrMamoru
Tsukuda (Yokohama City University, Kanagawa, Japan), and SCC-9
was purchased from the American Type Culture Collection (Manassas,
VA). Cell lines were maintained in a 5% CO2 atmosphere at 37°C in
RPMI-1640 (Invitrogen Corporation, Carlsbad, CA) for YCU-H891,
Dulbecco’s modified Eagle medium (Invitrogen Corporation) for KB
and SCC-9 with 10% fetal bovine serum (Life Technologies, Grand Is-
land, NY) and antibiotics, unless specified otherwise. For TGF-α (R&D
Systems, Minneapolis, MN) stimulation assays, cell lines were grown
in serum free medium for 24 hours before treatments. Gefitinib was pro-
vided by AstraZeneca (Wilmington, DE), and chlorpromazine (CPZ)
was purchased fromSigma-AldrichCorporation (St Louis,MO). Primary
antibodies (Abs) were diluted 1:2000, and secondary Abs were diluted
1:15,000. Rabbit anti-EGFR sera were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Mouse anti–phospho-EGFR (Y1068)
monoclonal Abs (mAbs), mouse anti–MEK1/2 mAbs, rabbit anti–
phospho-c-Raf (S338), rabbit anti–phospho-MEK1/2 (S221), rabbit
anti–phospho-ERK1/2 (T202/Y204), rabbit anti–phospho-Stat3
(Y705), rabbit anti-IκBα, rabbit anti–phospho-IκBα (S32/S36), rab-
bit anti–phospho-NF-κB p65 (S536), rabbit anti–c-Raf, and rabbit
anti–ERK1/2 sera were from Cell Signaling Technology (Beverly,
MA). Mouse anti–c-Myc mAbs were from Calbiochem (EMD Bio-
sciences, Darmstadt, Germany). Mouse anti–c-Cbl mAbs were from
BD Immunocytometry (San Jose, CA). Rabbit anti–phospho-Cbl
(Y774) mAbs were from Epitomics (Burlingame, CA). Mouse anti-
CIN85 mAbs were from Upstate Biotechnology (Lake Placid, NY).
Mouse anti-V5 mAbs were from Invitrogen. Mouse anti–β-actin mAbs
were from Sigma.Goat antirabbit and antimouseHRP-conjugated IgGs
were from Jackson ImmunoResearch Laboratories (West Grove, PA).
RNA Interference
The pSUPER-based strategy was adopted to knock down CIN85
expression. To generate CIN85 small hairpin RNA (shRNA), a 19-
nucleotide sequence (CAGCAATGACATTGACTTA) selected from
human CIN85 complementary DNA was annealed and ligated into
GFP-pSUPER knockdown vector.
Stable Transfection of HNSCC Cell Lines with an shRNA
Construct or Wild-type CIN85 Construct
Full-length CIN85 expression vector was previously described [14].
KB cells were transfected with 20 μg of CIN85 knockdown vectors
(designated as KB/KD cells), full-length CIN85 vectors (designated as
KB/OE cells), or corresponding control vectors by electroporation
methods and cultured for 48 hours. Clonal cell lines stably expressing
these constructs were then selected in medium containing 1 μg/ml G418.
We also generated clonal lines of YCU-H cells stably expressing either a
CIN85 shRNA construct or a full-length CIN85 construct.
RNA Extraction and Quantitative Reverse
Transcription–Polymerase Chain Reaction
Total RNAextraction and quantitative reverse transcription–polymerase
chain reaction (RT-PCR) assays were carried out essentially as described
previously [15]. TaqMan target mixes for human-CIN85, c-Myc and
18S rRNA (internal control) were purchased from Applied Biosystems
(Foster City, CA). Preliminary experiments showed that 18S rRNA
internal control works best in our quantitative RT-PCR assays. Triplicate
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data were analyzed with Sequence Detector software (Applied Bio-
systems). Data were expressed as a fold change compared with the
minimal gene expression score (taken as 1.0) in each experiment.
Proliferation Assays
Two thousand cells were cultured in 60-mm dishes for 96 hours, and
thereafter, the number of cells in each plate was counted in triplicate
assays every other day using a Coulter counter (Beckman Coulter,
Fullerton, CA). The mean values were used to generate growth curves.
Cell Viability Assays
Cell viability was determined using a Cell Proliferation Reagent
WST-1 (Roche Molecular Biochemicals, Mannheim, Germany) ac-
cording to the manufacturer’s instructions.
Protein Extraction and Immunoblot Analysis
Protein extractions and immunoblot analyses were carried out
essentially as described previously [15]. The signal intensity of spe-
cific bands was quantified using the ImageGauge software (Fuji Film,
Tokyo, Japan).
Ras Activation Assay
The amounts of active form of Ras (Ras-GTP) were measured
using Ras activation assay kit (Upstate Biotechnology) according to
the manufacturer’s instructions.
Confocal Immunofluorescence Microscopy
Cells were grown on poly-L-lysine–coated glass-bottom dish
(Matsunami, Osaka, Japan) for 24 hours in serum-free medium and
then cultured in the absence or presence of 100 ng/ml of TGF-α for
5 minutes. Cells were subsequently fixed with 3.7% formaldehyde
in PBS for 10 minutes, permeabilized in PBS containing 0.1% Triton
X-100 for 5 minutes, and blocked in PBS containing 1% bovine
serum albumin for 30 minutes. Cells were then incubated with mouse
anti-EGFR mAbs (1:50; Santa Cruz Biotechnology) for 45 minutes,
followed by a secondary Alexa Flour 594 goat antimouse Ab (1:500;
Molecular Probes/Invitrogen) for 30 minutes. Samples were analyzed
by confocal microscopy (Nikon A1; Nikon, Tokyo, Japan).
Statistical Analysis
Statistical analyses were carried out by the Mann-Whitney U test.
P < .05 was considered statistically significant.
Results
CIN85 Is Highly Expressed in HNSCCs in Advanced
Clinical Stage
To test a role of CIN85 in the progression of HNSCC, we measured
the expression levels ofCIN85messenger RNA (mRNA) in both tumor
and adjacent normal tissues obtained from 29 untreated patients with
oral squamous cell carcinoma. In 40% of tumor samples, more than
two-fold higher levels of CIN85mRNAwere observed, compared with
adjacent normal tissues obtained from the respective patient. The
mean value of relative CIN85 mRNA expression levels was higher in
tumor tissues (69.9 ± 4.4) than normal tissues (49.3 ± 3.7), albeit not
statistically significant. Notably, increased levels of CIN85 mRNA
in tumor samples significantly correlated with the existence of nodal
metastases (P = .0044) and advanced clinical stages (P = .028; Table 1).
No differences were observed between the expression levels of CIN85
and age, sex, tumor recurrence, or smoking habits (Table 1). We
found a positive correlation between CIN85 mRNA and protein levels
in tumor samples from different patients (Figure 1A). These results
strongly suggest that CIN85 is highly expressed in HNSCC samples
and that its expression levels are significantly associated with tumor
progression indicated by high frequencies of nodal metastases and ad-
vanced clinical stage.
CIN85 Upregulates the Growth Potential of HNSCC Cells
High levels of CIN85 expression in clinical samples prompted us
to determine whether CIN85 regulates cell growth potential using
HNSCC cell lines. To this end, we first tested expression levels of
EGFR and CIN85 in three HNSCC cell lines (Figure 1B). All three
HNSCC cell lines were positive for EGFR protein, albeit with con-
siderable variation in expression levels. Conversely, KB cells signifi-
cantly express CIN85 at both mRNA and protein levels, compared
with SCC9 and YCU-H891 cells. This expression profile suggests that
KB cells express higher levels of CIN85 and thus mimic a subset of
HNSCC with progressive phenotypes.
We next generated independent clonal KB cell lines of CIN85 knock-
down and full-length CIN85 overexpression (designated as KB/KD1,
KB/KD2, KB/OE1, and KB/OE2 cells), as described in Materials and
Methods. As shown in Figure 1C , expression levels of CIN85 mRNA
and protein were significantly decreased in KB/KD cells, whereas they
were markedly increased in KB/OE cells, compared with parental and
control cells.
Using these stable KB lines, we monitored the growth of parental
KB, vector control KB, KB/KD1, and KB/OE1 cells (Figure 1D). Be-
cause parental and vector control cells displayed similar proliferation
patterns, representative data of vector control cells are shown hereafter.
KB/KD1 cells demonstrated a lower rate of proliferation compared
with control cells, and the differences of growth at days 10 and 12 were
Table 1. Relationship between CIN85 Expression and Clinicopathologic Parameters.
n Mean Score of Relative Expression of CIN85 mRNA P
T stage
I and II 18 86.72 ± 37.36 .79
III and IV 11 42.25 ± 8.07
Nodal metastasis
Negative 10 21.84 ± 6.53 .0044
Positive 19 95.12 ± 35.47
Clinical stage
I and II 8 24.11 ± 8.04 .028
III and IV 21 87.28 ± 31.66
Recurrence
Negative 11 58.47 ± 29.91 .34
Positive 16 79.48 ± 37.87
Age (years)
<60 16 76.52 ± 38.01 .79
>60 13 61.64 ± 25.23
Sex
Male 21 56.16 ± 15.67 .59
Female 8 105.79 ± 76.79
Smoking
Brinkman score <400 13 97.06 ± 4.45 .31
Brinkman score >400 16 68.73 ± 9.91
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statistically significant (P < .05). In contrast, enforced overexpression of
CIN85 protein further enhanced the growth of these cells, and the dif-
ference of growth at day 12 was statistically significant (P < .05). These
results suggest that CIN85 upregulates the growth of HNSCC cells, at
least in part accounting for progressive phenotypes of the clinical sam-
ples with high CIN85 expression.
CIN85 Facilitates EGFR Internalization without Affecting
Its Phosphorylation
One of the characteristic functions of CIN85 is the regulation of
ligand-induced internalization of receptor tyrosine kinases (RTKs) in-
cluding EGFRs [12,13]. We thus determined whether CIN85 knock-
down affects EGFR internalization in KB cells after TGF-α stimulation
Figure 1. CIN85 upregulates the growth of HNSCCs. (A) CIN85 mRNA and protein expression in representative clinical samples. Total
RNA and proteins were extracted from the tissues of untreated patients with oral squamous cell carcinoma. CIN85 mRNA and protein
expression and phospho-ERK1/2 expression were evaluated by quantitative RT-PCR and Western blot analysis. CIN85mRNA expression
in no. 155 sample was taken as 1.0. In Western blots, β-actin served as a loading control. The intensity of bands was quantified and
normalized with respect to those of corresponding β-actin. The resulting values were expressed as the percentage in reference to that of
no. 212. (B) CIN85 mRNA and protein expressions and EGFR protein expression in three HNSCC cell lines (KB, YCU-H891, and SCC9) by
quantitative RT-PCR and Western blot assays. Total RNA and proteins were extracted from exponentially growing cells and subjected
to quantitative RT-PCR analysis and Western blots. In quantitative RT-PCR analysis (left panel), the level of CIN85 mRNA expression in
YCU-H891 was taken as 1.0. In Western blot analysis (right panel), the resulting values were expressed as the percentage in reference
to that of KB cells. (C) Establishment of stable CIN85-overexpressing and CIN85 knockdown KB cells. Either an shRNA construct for
CIN85 or a full-length CIN85 construct was transfected with KB cells. Independent clonal lines were designated as KB/KD1, KB/KD2, KB/
OE1, and KB/OE2. Expression levels of CIN85 mRNA (upper panel) and proteins (lower panel) in parental, vector ,control and transfected
cells were measured by quantitative RT-PCR or Western blots. In quantitative RT-PCR analysis, the level of CIN85 mRNA expression in
parental KB cells was taken as 1.0. In Western blot analysis, the resulting values were expressed as the percentage in reference to that
of KB/OE2 cells. Note that a full-length CIN85 transgene is V5-tagged, and thus, its product migrates slower than endogenous CIN85
on a gel (arrow). (D) Growth curves of control and transfected cells. Two thousands cells of the indicated cell lines were cultured for
96 hours and counted every other day. The results are representative of three independent experiments. The values at each point in-
dicate the average of triplicate dishes; bars, SD.
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(Figure 2A). Confocal microscopic analyses demonstrated that TGF-
α–induced EGFR internalization (TIEI) was clearly observed in KB/
mock cells. In contrast, CIN85 knockdown (KB/KD1 and KB/KD2
cells) significantly inhibited TIEI. To directly test whether this in-
hibition is not secondary to CIN85 knockdown, we reintroduced
full-length CIN85 gene into KB/KD1 cells and found that TIEI gets
normalized in these cells (Figure W1). Treatment of KB/mock cells
with 20 μM of CPZ, an inhibitor of clathrin-mediated RTK internali-
zation [16], also partially inhibited TIEI. Consistent with previous
reports [12,13], these results suggest that CIN85 facilitates EGFR in-
ternalization in HNSCC cells.
We next questioned whether EGFR internalization facilitated by
CIN85 affects the expression levels of EGFR and phospho-EGFR in
KB cells (Figure 2B). Immunoblot assays of EGFR and phospho-EGFR
demonstrated that, on TGF-α stimulation, the levels of total cellular
EGFR proteins remained unchanged for 30 minutes and slightly de-
creased at 120 minutes in both KB/mock and KB/KD1 cells to a simi-
lar extent, probably due to a partial degradation of the EGFR protein.
The levels of basal and TGF-α–stimulated phospho-EGFR proteins
were comparable between KB/mock and KB/KD1 cells. These suggest
that CIN85 facilitates EGFR internalization without altering the levels
of total EGFR protein and the phosphorylation of EGFR in HNSCC
cells. Thus, growth inhibition in KB/KD1 (Figure 1D) was not sim-
ply due to decreased phosphorylation of EGFR. A possible explana-
tion for the lack of CIN85’s effect on EGFR phosphorylation could
be that a majority of TGF-α–bound EGFRs are processed through
the recycling back pathway [12]. We treated KB/mock cells and KB/
KD1 cells with gefitinib, an EGFR-specific inhibitor, and assessed their
survival (Figure 2C). Control and KB/KD1 cells exhibited similar sen-
sitivity to gefitinib, again suggesting that CIN85 does not affect TGF-
α–induced phosphorylation of EGFR (i.e., signal intensity of EGFR)
in HNSCC cells.
CIN85 Promotes Activation of the Ras-ERK Pathway
Required for Cell Growth of HNSCCs
To further elucidate the molecular mechanism by which CIN85 en-
hances proliferation of KB cells, we analyzed the phosphorylation of
signaling molecules downstream of EGFR including c-Cbl, mitogen-
activated protein kinases (MAPKs), and NF-κB byWestern blot assays.
No significant differences were observed in the expression levels of
Figure 2. CIN85 facilitates EGFR internalization without affecting its phosphorylation. (A) Confocal microscopic assays for EGFR inter-
nalization in KB/mock and KB/KD cells. The indicated cells were grown on poly-L-lysine–coated glass-bottom dishes (IWATANI) for 24 hours
in serum-free medium, and half of the dishes were stimulated with 100 ng/ml of TGF-α for 5 minutes. For inhibition of clathrin-mediated
EGFR internalization, KB/mock cells were treated with 20 μM of CPZ for 30 minutes before TGF-α stimulation (right panel). Cells were then
fixed, and the localization of EGFR was visualized with anti-EGFR mAb and a secondary Alexa Flour 594–conjugated antimouse Ab. The
results are representative of three independent experiments. (B) Western blot assays for EGFR and phospho-EGFR (p-EGFR) protein
in KB/mock and KB/KD1 cells. The exponentially growing cells were stimulated with 100 ng/ml of TGF-α for the indicated times, and cell
lysates were prepared. β-Actin was served as a loading control. Relative expression (R.E.) was calculated as the ratio to the level of un-
stimulated KB/mock cells (taken as 1.0). (C) Effect of CIN85 expression on cell sensitivity for gefitinib. Cells were treated with the indi-
cated concentrations of gefitinib for 72 hours, and then cell viability was determined by cell proliferation assays. The values at each
point indicate the mean of triplicate wells; bars, SD.
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Figure 3. CIN85 preferentially promotes activation of the Ras-ERK pathway critical for the growth of HNSCCs. (A and B)Western blot assays
for phospho-c-Raf, -MEK1/2, and -ERK1/2 in KB/mock, KB/KD1, KB/empty, and KB/OE1 cells. Cells were treated with 100 ng/ml of TGF-α for
the indicated times, and cell lysates were prepared. Relative expression (R.E.) was calculated as described in Figure 2. The results are rep-
resentative of three independent experiments. (C) Effect of CIN85 expression on Ras activation in KB/mock and KB/KD cells. Cells were
treated with 100 ng/ml of TGF-α for the indicated times, and the abundance of the activated forms of Ras (Ras-GTP) and total cellular
Ras proteins was determined. The levels of specific bands were quantified, and those of Ras-GTP were normalized with respect to those
of corresponding Ras. The resulting values were expressed as the percentage in reference to that of KB/mock stimulated with TGF-α for
5 minutes. The results are representative of two independent experiments. (D) Gefitinib blocks CIN85-induced enhancement of Ras activa-
tion. Cells were treated with the indicated concentrations of gefitinib for 30 minutes before TGF-α stimulation, and the abundance of acti-
vated forms of Ras (Ras-GTP) and total cellular Ras proteins was determined. The resulting values were expressed as the percentage in
reference to that of KB/OE2 stimulated with TGF-α for 5 minutes. The results are representative of two independent experiments. (E) Effect
of CIN85 expression on c-Myc expression in KB/mock and KB/KD cells. Cells were treated with 100 ng/ml of TGF-α for the indicated times,
and total RNA and proteins were extracted. Relative expression of c-Myc mRNA was determined by quantitative RT-PCR assays (upper
panel). The values are the mean ± SD of three independent experiments. *P < .05. The levels of c-Myc protein were detected by Western
blot assays (lower panel). β-Actinwas served as a loading control. The resulting valueswere expressed as the percentage in reference to that
of KB/mock stimulated with TGF-α for 120 minutes.
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IκBα, phospho-IκBα, phospho-p65 NFκB, c-Cbl, and phospho-c-Cbl
between control, KB/OE1, and KB/KD1 cells regardless of TGF-α
stimulation (data not shown). Conversely, the levels of phospho-c-
Raf, -MEK1/2, and -ERK1/2 were significantly inhibited in KB/
KD1 cells, whereas they were enhanced in KB/OE1 cells (Figure 3,
A and B). Similar data were also obtained using KB/KD2 and KB/
OE2 cells (Figure W2).
To further determine whether CIN85 functions more upstream of
the MAPK cascade, we analyzed the activities of Ras in KB/mock,
KB/KD1, and KB/KD2 cells (Figure 3C ). On TGF-α stimulation,
the levels of Ras-GTP (activated form of Ras) were significantly inhib-
ited in KB/KD cells, suggesting that CIN85 promotes Ras activation
downstream of EGFR in HNSCC cells. We next tested whether an
EGFR inhibitor, gefitinib, could cancel CIN85-induced enhancement
of Ras activation in KB/OE1 cells. As a result, we found that gefitinib
significantly suppressed Ras activation in KB/OE1 cells (Figure 3D),
suggesting that CIN85’s effect on activation of the Ras/MAPK pathway
absolutely requires EGFR stimulation.
Finally, we determined the expression levels of c-Myc mRNA and
protein between KB/mock and KB/KD1 cells (Figure 3E ) because
c-Myc is one of the important targets of the Ras-ERK pathway that is
critical for tumor progression in a variety of tumors including HNSCCs
[17,18]. Consistent with the current results that CIN85 promotes acti-
vation of the Ras-ERK pathway, expression levels of c-Myc were signifi-
cantly decreased in KB/KD1 cells with or without TGF-α, compared
with KB/mock cells.
Discussion
To date, there are only two reports examining the expression levels of
CIN85 in the clinical samples of human cancer. In human gliomas,
CIN85 is expressed at higher levels than in normal brain [19]. In
human melanoma, expression levels of CIN85 are higher in tumors
compared with adjacent normal tissues [20]. These results are thus con-
sistent with our present study on HNSCC and indicate that CIN85 is
involved in the tumor development of certain types of human malig-
nancies. In our study, we further analyzed the correlation between the
levels of CIN85 expression and clinicopathologic parameters and found
that CIN85 expression is more pronounced in HNSCC tumor tissues
obtained from patients in advanced clinical stages, providing the first
evidence that CIN85 expression is associated with tumor progression
in human cancer. Considering the limited number of samples used
in our study, further accumulation of data is required to consolidate
the significance of CIN85 expression in HNSCC, especially as a prog-
nostic marker.
A functional role of CIN85 in tumorigenesis has thus far been poorly
characterized. A previous article showed that CIN85 is critical for the
maintenance of invasive phenotype in breast cancer cells [21]. In the
present study using HNSCC cell lines, we found that CIN85 upregu-
lates the growth of HNSCCs through potentiating EGFR-mediated
Ras-ERK activation. In addition, ERK phosphorylation was more
pronounced in clinical samples expressing high levels of CIN85 (Fig-
ure 1A). Notably, a previous study showed that ERK activation is en-
hanced in HNSCCs with advanced regional lymph node metastasis
[4], consistent with our result that increased CIN85 expression is asso-
ciated with nodal metastases (Table 1). These findings suggest that
CIN85 is considered as a critical mediator of EGFR-induced ERK ac-
tivation and consequent tumor progression in HNSCC. We have thus
unraveled a new function of CIN85: a mediator of EGFR signaling to
the Ras-ERK pathway.
The precise molecular mechanisms by which CIN85 regulates EGFR-
mediated Ras activation remain to be elucidated. Nevertheless, a couple
of possibilities could be envisioned. Consistent with previous studies
[12,13], CIN85 facilitated ligand-induced EGFR internalization in
HNSCC cells (Figure 2A). Because of the classic conceptual framework,
EGFR internalization was considered to downregulate EGFR signaling
and cause tumor suppression. However, accumulating evidence suggests
that EGFR continues to signals in cytoplasm as well as on plasma mem-
brane. In this process, the endosome functions as a critical compart-
ment that enables the propagation of signaling downstream of EGFR.
Signals generated at endosomes are sufficient for the growth of epithelial
cells presumably through promoting ERK activation [22]. Intriguingly,
ERK is colocalized with activated Ras on rasosomes that are Ras-enriched
small cytosolic nanoparticles [23]. Thus, a provocative possibility is that
CIN85 plays a key role in connecting early endosomes with rasosomes
and contributes to activation of the Ras-ERK pathway. This possibility,
taken together with the fact that in HNSCC the major EGFR ligand,
TGF-α, mainly sorts EGFR in the recycling back loop [24], accounts
at least in part for the mechanism of CIN85-mediated HNSCC tumori-
genesis. Thus, CIN85 facilitates TGF-α–induced internalization of
EGFRs, which are constantly supplied in the recycling back-loop. These
cytoplasmic EGFRs continue to stimulate the Ras-ERK pathway.
Another possibility is that CIN85 regulates Ras activation by amecha-
nism independent of EGFR internalization. First, overexpression of focal
adhesion kinase (FAK) promotes Ras activity in malignant astrocytoma
cells [25]. Because FAK is a binding partner for CIN85 [26],CIN85may
enhance Ras activity through its interaction with FAK in HNSCC cells.
Second, Sprouty 2 plays a critical role in tumor formation by H-Ras–
transformed human fibroblasts [27]. Given that Sprouty 2 is also a bind-
ing partner for CIN85 [28], CIN85 may regulate Ras activity through
altering the function of Sprouty 2. Further work is needed to clarify
these possibilities.
In contrast to our current study, Tossidou et al. [29] previously sug-
gested a negative regulatory role of CIN85 in ERK phosphorylation
in podocytes. Of note, podocytes poorly express CIN85 and instead
abundantly express CD2AP, a paralog of CIN85 [30]. In addition, mice
deficient in CD2AP die around 6 weeks of age because of renal failure,
and podocyte-specific expression of CD2AP corrects this phenotype
[30]. Given that CIN85 and CD2AP compete for their binding part-
ners, CD2AP may play a more dominant role in Ras-ERK activation in
podocytes. Thus, CD2AP/CIN85 balance could influence their roles
in RTK response depending on cell type.
In conclusion, our current findings suggest that CIN85 overexpres-
sion is associated with tumor development and progression in a subset
of HNSCC. Moreover, we uncovered a novel function of CIN85 as
a promoter of the Ras-ERK cascade downstream of TGF-α/EGFR
in human cancer. Given that the Ras-ERK pathway is critical for the
maintenance of malignant phenotypes of HNSCCs, CIN85 can be a
potential therapeutic target in a subset of HNSCC in the future.
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Figure W1. Reintroduction of full-length CIN85 into KB/KD cells. KB/KD1 cells were transfected with empty vector or full-length CIN85 gene.
The cells were grown on poly-L-lysine–coated glass-bottom dishes (IWATANI) for 24 hours in serum-free medium, and half of the dishes
were stimulated with 100 ng/ml of TGF-α for 5 minutes. Cells were then fixed, and the localization of EGFR was visualized with anti-EGFR
mAb and a secondary Alexa Flour 594–conjugated antimouse Ab. The results are representative of three independent experiments.
Figure W2. (A and B) Western blot assays for phospho-ERK1/2 and ERK1/2 in KB/mock, KB/KD2, KB/empty, and KB/OE2 cells. Cells
were treated with 100 ng/ml of TGF-α for the indicated times, and cell lysates were prepared. Relative expression (R.E.) was calculated
as described in Figure 2. The results are representative of two independent experiments.
